BPIQ Blog

Merck (MRK.N) reported today that it is buying ARQL for over a 100% premium from Friday's closing price (https://reut.rs/341eQv1). This...

Congrats to ARQL and especially CLL (a type of blood cancer) patients on the impressive early-stage data presented today at a poster...

ARQL pleasantly surprised investors yesterday on its quarterly call by giving two positive clinical trial updates. First, and most...